Intensity Therapeutics, Inc. (INTS) · Nov 5, 2026 · Earnings
Miss — EPS $(1.09) vs approximately $(0.94) consensus
Intensity Therapeutics earnings show an EPS miss despite restarting enrollment in both cancer trials; the Q1 2027 safety review remains the key validation point.
Intensity Therapeutics is a late-stage oncology biotech trying to move INT230-6 from promising early data into two larger registration-oriented studies, while operating with a limited cash base and continued dependence on equity financing. Its prior disclosures said the balance sheet extended operating runway into Q2 2027, but also that additional capital would be needed to keep advancing the programs.
The quarter missed the limited published earnings bar. Third-quarter EPS was $(1.09), versus an approximately $(0.94) consensus estimate, even though the loss was narrower than $(1.55) a year earlier. There is no product revenue to assess; the earnings signal is mainly that spending is rising again as clinical work restarts.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Loss per share, basic and diluted (Income Statement) | $(1.09) | $(1.55) | $(0.94) |
| Research and development (Income Statement) | $2.429M | $1.553M | |
| Net loss (Income Statement) | $(3.544)M | $(2.671)M | |
| Cash and cash equivalents (Balance Sheet) | $8.494M (-28.8%) |
Operationally, the filing confirms progress rather than a new breakthrough. INVINCIBLE-3 enrollment restarted at several U.S. sites during the third quarter after being paused for funding constraints, while INVINCIBLE-4 enrollment and treatment had already restarted in July. That advances the pipeline from pause mode back toward execution, but broader site activation remains conditional on obtaining sufficient incremental funding. 〔0〕 〔1〕
The breast-cancer data are encouraging but still too small to remove clinical risk. The first seven INT230-6-treated patients produced a 71% pathological complete response rate versus 42% in the seven-patient control cohort, alongside fewer grade 3 adverse events. That supports the treatment thesis, but the sample is preliminary and the trial is specifically waiting for an independent safety review after earlier localized skin irritation.
Liquidity remains the main constraint on how fast this progress can scale. The company raised $1.5 million through its ATM during the quarter, but cash declined to $8.5 million from $11.9 million at year-end while trial spending resumed. The filing therefore improves the operating story, but does not remove the financing overhang that previously forced a Phase 3 pause.
Bottom line: The pipeline is moving again and the early breast-cancer signal remains promising, but the quarter itself missed expectations and cash is being consumed before the key Q1 2027 safety checkpoint. This is a modestly weaker update overall, not a change in the underlying clinical thesis.
Q1 2027 IDMB review of INVINCIBLE-4 safety data
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!